Anti-HLA DRA Antibody [IPO-10] - BSA and Azide free (A252027)

Anti-HLA DRA Antibody [IPO-10] - BSA and Azide free

Mouse monoclonal [IPO-10] antibody to HLA DRA.

This antibody defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37, and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnosis of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, and RPMI-8226 (50% of cells). This antibody does not label T cell lines, blood granulocytes, thymocytes, or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This antibody labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. This antibody reacts with AMML cells and in a majority of Hodgkins disease cases a significant percentage of affected lymph node cells were detected.

Flow Cytometry, IF

Flow Cytometry: 1-2 µg/million cells, IF: 1-2 µg/ml

Human, Monkey

Spleen cells of a patient with hairy cell leukemia (Daudi cells).

Mouse

Monoclonal

IPO-10

kappa

Protein A/G chromatography.

1 mg/ml

~36 kDa

Liquid

Supplied in 10mM Phosphate Buffered Saline; without Sodium Azide and carrier free.

Shipped at 4°C. Store at 4°C.

This monoclonal antibody is also available in a different formulation with BSA and Sodium Azide - Anti-HLA DRA Antibody [IPO-10] (A248847).